HighTower Advisors
CRSP icon

HighTower Advisors’s CRISPR Therapeutics CRSP Stock Holding History

HighTower Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2
Closed -$1K – 3455
2021
Q4 		$1K Buy
+2
New +$175 ﹤0.01% 3255

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HighTower Advisors's CRSP Position: Q1 2026 in Review

HighTower Advisors reduced its CRISPR Therapeutics (CRSP) stake by 9.1% in Q1 2026, selling an estimated $132K and leaving 25,004 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2070.

HighTower Advisors first reported a position in CRSP in Q2 2018 and has held it in 32 quarters since. The position peaked at $6.49M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • HighTower Advisors held 25,004 shares of CRISPR Therapeutics worth $1.19M as of Q1 2026.
  • HighTower Advisors sold 2,505 CRISPR Therapeutics shares in Q1 2026, an estimated $132K.
  • CRISPR Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #2070 holding.
  • HighTower Advisors first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 32 quarters since.
  • HighTower Advisors's CRISPR Therapeutics position peaked at $6.49M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.